Jankowski, T., Kowal-Rosinska, M., Müller, V., Sezer, A., Csoszi, T., Nagy, T., Ramlau, R., Soter, S., Bobora, R., Amurariti, F., Volovat, C. D., Sirbu, D. E., Mender, I., Girotti, R., Mitsunaga, M., Tudos, O., Failor, M., Vitoc, V., Gryaznov, S., Zaporojan, V. (2026). Phase 2 study of PFS in third-line immune checkpoint inhibitor–resistant advanced NSCLC treated with the telomere-targeting agent ateganosine (THIO; 6-thio-2'-deoxyguanosine) sequenced with ICI.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e20610